Addressing one of the first substantive rulings in the Risperdal litigation in California, an appeals court has potentially reinstated hundreds of lawsuits after partially reversing a key decision on federal preemption.

The lawsuits allege that anti-psychotic drug Risperdal, made by Johnson & Johnson’s Janssen Pharmaceuticals, causes boys to develop breasts—a condition called gynecomastia. In 2017, Los Angeles Superior Court Judge William Highberger granted summary judgment in lawsuits coordinated in California state courts based on federal preemption.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]